Axicabtagene-ciloleucel: Haemophagocytic-lymphohistiocytosis and cytokine-release syndrome: case report.

However on day 38 after the initiation of axicabtagene-ciloleucel therapy, the patient died due to haemophagocytic-lymphohistiocytosis and grade 5 cytokine-release syndrome. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In this large multi-center observational cohort study of 275 patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) treated with axicabtagene-ciloleucel, one patient [ I age and sex not stated i ] was described, who developed fatal haemophagocytic-lymphohistiocytosis and fatal cytokine-release syndrome during treatment with axicabtagene-ciloleucel for R/R LBCL [ I dosage and route not stated i ]. [Extracted from the article]